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Abstract
Background: Medical devices and in vitro diagnostic tests (IVD) are vital components of health delivery systems but
access to these important tools is often limited in Africa. The regulation of health commodities by National
Regulatory Authorities is intended to ensure their safety and quality whilst ensuring timely access to beneficial new
products. Streamlining and harmonizing regulatory processes may reduce delays and unnecessary expense and improve
access to new products. Whereas pharmaceutical products are widely regulated less attention has been placed on the
regulation of other health products. A study was undertaken to assess regulation of medical diagnostics and medical
devices across Partner States of the East African Community (EAC).
Methods: Data was collected during October 2012 through desk based review of documents and field research, including
face to face interviews with the assistance of a structured questionnaire with closed and open ended questions. Key
areas addressed were (i) existence and role of National Regulatory Authorities; (ii) policy and legal framework for
regulation; (iii) premarket control; (iv) marketing controls; (v) post-marketing control and vigilance; (vi) country capacity
for regulation; (vii) country capacity for evaluation studies for IVD and (viii) priorities and capacity building for
harmonization in EAC Partner States.
Results: Control of medical devices and IVDs in EAC Partner States is largely confined to national disease programmes
such as tuberculosis, HIV and malaria. National Regulatory Authorities for pharmaceutical products do not have the
capacity to regulate medical devices and in some countries laboratory based organisations are mandated to ensure
quality of products used. Some activities to evaluate IVDs are performed in research laboratories but post market
surveillance is rare. Training in key areas is considered essential to strengthening regulatory capacity for IVDs and other
medical devices.
Conclusions: Regulation of medical devices and in vitro diagnostics has been neglected in EAC Partner States.
Regulation is weak across the region, and although the majority of States have a legal mandate to regulate medical
devices there is limited capacity to do so. Streamlining regulation in the EAC is seen as a positive aspiration with
diagnostic tests considered a priority area for harmonisation.
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Background
The East African Community (EAC) is a regional inter-
governmental organization of five Partner States, namely
the Republic of Kenya, the Republic of Uganda, the
Republic of Burundi, the Republic of Rwanda and the
United Republic of Tanzania. Together the five states cover
an area of approximately 1.8 million square kilometres and
a population of over 135 million people. In addition
to promoting trade and economic growth a priority
consideration for the EAC is the health of the population.
Health indicators across the region show increasing life
expectancies [1] but despite progress made the region
remains beset by conditions such as tuberculosis,
HIV/AIDS, other sexually transmitted infections and
in some geographic areas malaria [2-4]. The 1999
founding Treaty for the Establishment of the East
African Community articulates a policy to “harmonize
national health policies and regulations and promoting
the exchange of information on health issues in order to
achieve quality health within the Community” [5]. A
program to harmonize registration of medicines within
EAC Partner States was launched in 2012 under the
leadership of the EAC Medicines and Food Safety Unit
[6]. The project forms part of a wider programme, the
African Medicines Regulatory Harmonisation (AMRH)
Initiative which is coordinated by the African Union’s
New Partnership for Africa’s Development (NEPAD). The
overall aim of the AMRH Programme is to improve public
health in Africa by increasing access to good quality, safe
and effective medicines through the harmonization of
medicines regulations, including reduction of the time
taken to register essential medicines for the treatment of
diseases [6].
In addition to medicines other medical products of
benefit to patients include medical devices and diagnostic
tests. Such products make a major contribution to health
as many important diseases and conditions require diag-
nostic guidance to ensure appropriate care. This includes
therapeutic use of drugs, where delayed diagnosis can
result in deterioration of the patient and, for infectious
conditions, continued transmission and spread of disease.
The regulation of products for human health by National
Regulatory Authorities (NRAs) is intended to ensure
their safety and quality whilst ensuring timely access
to beneficial new products. Safety may be assured by
pre-market scrutiny of new products and by post- market
surveillance to ensure quality and performance are
maintained. Regulatory controls imposed should be
proportionate to the risk of harm to individual or
public health. The market dynamics for medical devices
and diagnostic products for health are distinct from those
for pharmaceutical products and their regulation requires
a different approach to that for medicines. Medical devices
present a wide range of technologies, ranging from the
simple band aid to very complex machinery. Quality of
design and manufacture is important, particularly for
devices that use electrical power where a malfunction
could cause serious injury or death or for products that
use toxic reagents or expose the user to risk of infection.
Diagnostic tests vary in complexity, ranging from
simple colorimetric dip-stick devices to sophisticated
computerised instruments and for some conditions
there is a proliferation of products suitable for use at
different levels of the healthcare delivery system. Most
diagnostic tests fall into the category of in vitro diagnostics
(IVDs), where they are used to test specimens obtained
from the patient. Unlike medicines or vaccines the product
is not ingested and the risk of causing harm is related
to the performance of the device and likelihood of a
malfunction and the consequences of obtaining an
incorrect test result. The Global Harmonization Task
Force have recommended a four tier risk classification
system for medical devices and diagnostics where risk is
defined as the combination of the probability of occurrence
of harm and the severity of that harm [7].
Reagents such as microbiological stains or culture media
fall into the lowest category as they pose little hazard
whereas for tests used to screen blood products for deadly
diseases such as HIV an incorrect result could have
serious consequences, including onward transmission of
the disease. Such high risk products require more stringent
regulation, including studies of clinical performance
to determine their efficacy in the target population.
Access to IVDs and other medical devices in developing
countries is currently limited by their availability and cost
and in addition many diagnostic tests require laboratory
facilities and trained personnel that are not readily
available in Africa. A new generation of devices are
being developed for diagnosing important diseases that
promise significant benefit to public health. These include
tests for use at point-of-care that do not require referral to
specialist facilities [8]. It is important that patients in devel-
oping countries have timely access to these products and
that they are made available at affordable prices. Regulation
of medical devices in developing countries is weak and this
is particularly a problem with diagnostic tests [9]. In
countries that do not regulate IVDs, they may be sold with
little or no evidence of their efficacy. Where controls do
occur they can act as a barrier to products entering the
country [10]. An example is the delayed marketing of a
point-of-care device for enumerating CD4 cells to enable
patients with HIV to access therapy. The requirement
for clinical trials in individual countries has resulted
in considerable duplication of effort with little or no
scientific gain, and has increased costs and delayed their
introduction in some African countries by years.
In accordance with EAC policy to improve public
health through harmonized regulation, a regional survey
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was undertaken during 2012 of the regulation of medical
diagnostics and medical devices in the East African
Community Partner States. The aim of the survey was to
assess capacity and current practices across the Partner
States for regulation of medical diagnostics (including
In-vitro Diagnostics) and medical devices and the capacity
to undertake pre and post market assessment of quality,
safety and effectiveness. We hereby report the findings of
the study and recommendations made following review of
the data by a panel of technical experts drawn from EAC
partner states.
Methods
Data was collected during October 2012 through desk
based review and field research, including face to face
interviews. Information was collected with the assistance
of a structured questionnaire containing both closed and
open ended questions [see Additional file 1: Appendix
S2 for detailed questionnaire]. Questions were framed to
collect data on each of the essential features of a regulatory
program for medical devices as described in guidelines
published by the World Health Organisation [11]. The
questionnaire addressed in vitro diagnostic devices and
medical devices using the following definitions adapted
from guidance issued by the Global Harmonization Task
Force, a voluntary group of representatives from medical
device regulatory authorities and trade associations from
Europe, the United States of America (USA), Canada,
Japan and Australia [12].
A medical device (MD) is an instrument, apparatus,
implant, in vitro reagent, or other similar or related
article, which is intended for use in the diagnosis of
disease or other conditions, or in the cure, mitigation,
treatment, or prevention of disease, or intended to affect
the structure or any function of the body and which does
not achieve any of its primary intended purposes through
chemical action within or on the body.
An ‘in vitro diagnostic device’ (IVD) is a medical device
which is a reagent, reagent product, calibrator, control
material, kit, instrument, apparatus, equipment, or system,
whether used alone or in combination, intended by the
manufacturer to be used in vitro for the examination of
specimens, including blood and tissue donations, derived
from the human body, solely or principally for the purpose
of providing information concerning a physiological or
pathological state.
Key areas addressed were (i) existence and role of
National Regulatory Authorities; (ii) policy and legal
framework for regulation; (iii) premarket control; (iv)
marketing controls; (v) post-marketing control and vigi-
lance; (vi) country capacity for regulation; (vii) country
capacity for evaluation studies for IVD and (viii) priorities
and capacity building for harmonization in EAC Member
States.
Each Partner State was visited to enable interview
with key stakeholders. Interviewees were selected on the
recommendation of country experts. Both mainland
Tanzania and the semi- autonomous territory of Zanzibar
were consulted. Where experts were not available for
interview information was sourced from documented
evidence. In addition to the completed questionnaires
written reports were received from country experts.
Information sources used in the study are summarised in
Table 1 and a list of documents accessed is available in the
Additional file 2: Table S1.
Following compilation, the data was reviewed by a panel
of experts from the Republic of Kenya, the Republic of
Uganda, the Republic of Burundi and the United Republic
of Tanzania (Mainland and Zanzibar), including repre-
sentatives of Ministries of Health, National Regulatory
Authorities, National Medical Laboratories and Public
Health Regulatory Authorities. Representatives of medical
diagnostics manufacturers were also present.
Ethical review was not applicable to this study which
accessed and collated information in the public domain.
No ‘study subjects’ participated in the study, no human
data or materials were collected and no interventions
Table 1 Summary of evidence sources
Country Documents
reviewed
Organisations interviewed
(Number of persons)
Burundi 1 i. Ministry of Health
ii. Department of Pharmacy, Medicines and
Laboratory
Kenya 17 i. Pharmacy and Poisons Board (3)
ii. National Quality Control and Medical
Devices Laboratory
iii. Kenya Medical Laboratory Technicians
and Technologists Board (2)
Rwanda 4 No organisations interviewed
Tanzania
(Mainland)
11 i. Tanzania Food and Drugs Authority (2)
ii. Private Health Laboratories Board
Tanzania
(Zanzibar)
6 i. Zanzibar Food and Drugs Board (2)
ii. Central Medical Stores, Ministry of Health
and Social Welfare
iii. Chief Pharmacist, Ministry of Health and
Social Welfare
Uganda 8 i. National Drug Authority (3)
ii. Pharmacy Division, Ministry of Health
iii. Uganda National Bureau of Standards (2)
iv. Allied Health Professionals Council
v. Medilab (Laboratory supplies company)
vi. Central Public Health Laboratories
Total 47 16 (24)
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were performed. All persons interviewed agreed to do
so by prior appointment as part of their professional
attachment to the institutions. This study was undertaken
at the request of the Council of Ministers of Health of the
East African Community partner states.
Results and discussion
Reports were compiled from all five partner States. A
total of 24 interviews were conducted representing
16 organisations and 47 documents were collated
(Table 1).
Legislative and policy framework
Four Member States, Burundi, Kenya, Rwanda and
Tanzania (Mainland and Zanzibar) reported legislation
in the form of Acts of Parliament addressing products
for health, including medical diagnostics and medical
devices (Table 2). Both Kenya and Tanzania Mainland
reported legislative inconsistencies relating to medical
devices used in laboratories, with some duel responsibility
for their control. The fifth Partner State, Uganda has
legislation regarding the control of drugs (National Drug
Policy and Authority Act 1993) but no provision for the
regulation of medical products other than general legislation
for all commodities which are defined as ‘any article,
product or thing which is or will ultimately be the
subject of trade or use’. (The Uganda National Bureau
Of Standards Act 1983).
However, guidelines on use of medical diagnostic
products are being developed by the Allied Health
Professionals Council (AHPC) of Uganda. The AHPC is
mandated by an Act of Parliament to regulate medical la-
boratory professionals (among other Allied Health
Professional workers) and any other matter related to
the practice of the professionals.
All EAC Partner States identified one or more regulatory
bodies for medical products with the exception of Rwanda
that has instigated a taskforce to oversee the establishment
of a Food and Drug Authority. Whereas in all States
medicines are regulated by either a Pharmacy Board
or a Food and Drugs Authority there is little capacity
for regulation of medical devices or IVDs. Where
medical devices are controlled it is largely within disease
specific programmes such as tuberculosis, malaria or
HIV/AIDS with the Department of Health or international
donors guiding procurement decisions rather than
guidance from a national regulatory authority. Two lists of
approved products were supplied by respondents to the
questionnaire. The Private Health Laboratories Board in
Tanzania list included IVDs for HIV, malaria, hepatitis
and syphilis and a number of Haematology and Chemistry
Analysers. The Kenyan National AIDS and STI Control
Programme (NASCOP) provided a list of diagnostic
products approved for HIV, hepatitis B and C and
syphilis. One country, Tanzania, reported that public
procurement was linked to regulation through con-
sultation with the Private Health Laboratories Board.
Both Burundi and Uganda require authorization of
importation.
Some countries reported dual responsibility for diagnostic
devices where more than one agency is mandated and
some tensions were evident between laboratory-based
organizations who evaluate diagnostic test performance
and agencies whose primary activities lie in the regulation
of medicines. Although the focus of regulatory activities
was pharmaceuticals some countries are taking steps
towards strengthening diagnostics regulation, includ-
ing Tanzania who are receiving support through a
project with the World Health Organisation. New
guidelines are under consideration and are expected
to result in some realignment of activities with the
Tanzanian Food and Drug Authority assuming some
duties currently under the remit of the Private Health
Laboratories Board. Policies in Kenya are similarly
under review with the aim to better define the respective
roles of the Kenya Medical Laboratory Technicians
and Technologist Board (KMLTTB) which has responsi-
bility for the quality of medical laboratory activities
and the Pharmacy and Poisons Board which regulates
medicines.
Table 2 Regulatory legislature and health policy in EAC Member States and territories
Legislation for
medical devices
National
Health Policy
National Health
Laboratory Policy
Guidelines National Regulatory Authority
Burundi Yes na na na Directorate of Pharmacies, Medicines and Laboratories
Kenya Yes Yes Yes Yes Kenya Medical Laboratory Technicians and Technologist
Board/Pharmacy and Poisons Board
Rwanda Yes Yes na Yes Task force to set up FDA, but diagnostics not yet included
Tanzania Mainland Yes Yes P Yes Tanzania Food and Drug Authority/Private Health Lab Board
Tanzania Zanzibar Yes Yes na Yes Zanzibar Food and Drugs Board
Uganda Yes Yes National Drug Authority/Allied Health Professionals Council
of Uganda
na: Not available; P: Aspects of laboratory policy incorporated in the National Health Policy.
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Pre-market regulation
Whereas some regulatory activity was reported in each
Partner State more detailed questioning revealed that
with the exception of Tanzania pre market regulation
of medical devices and IVDs by National Regulatory
Authorities is largely absent across the EAC (Table 3).
No audit visits to manufactures to assess quality systems
are currently undertaken by EAC Partner States. There is
some scrutiny of products for the control of TB, malaria,
HIV and other STIs and while some States accept
products approved by donor agencies without further
testing others choose to undertake pre market testing
of IVDs in local laboratories.
Some harmonization of regulatory processes was
observed with cooperation between the Food and
Drug Authorities of Tanzania mainland and Zanzibar
with mutual recognition of some activities. Tanzania
also reported that for products with prior regulatory
approval from a stringent National Regulatory Authority
(Canada, Japan, Australia, EU and USFDA) or pre-
qualification by WHO could be reviewed using an
abridged dossier.
Market and post market controls
In the absence of regulatory capacity for medical devices
and IVDs market controls in EAC Partner States are
not specific for these products. Three States, Burundi,
Kenya and Tanzania require manufacturers to have a
local agent with legal accreditation prior to registering a
product for distribution in the country. Authorization
for import is required in Tanzania and Uganda, with
some enforcement in Tanzania through warehouse
inspections.
Advertising controls were reported in Burundi, Tanzania
and Uganda with some vetting and pre approval required.
Post market regulation was reported as being reactive
rather than proactive. Tanzania and Uganda reported that
reactive investigations were undertaken if problems
were reported. In Rwanda post market monitoring is
undertaken by Programmes (HIV/AIDS, TB etc.). The
Private Health Laboratories Board in Tanzania was
the only organization that reported a mechanism for
tracking medical devices or guidelines for recalling
substandard medical devices or IVDs, although some
other States reported mechanisms for reporting and
recall of pharmaceuticals.
National capacity
Data supplied by Member States suggests that capacity
to regulate either medical devices or diagnostic tests
within the EAC is limited. Capacity is divided between
persons with laboratory based technical expertise regarding
the use of medical devices and persons with regulatory
experience of pharmaceuticals but little or no knowledge of
IVD or other medical devices. Regulation of some IVD that
are considered high risk to individual or public health
requires knowledge of their efficacy obtained from clinical
trials to assess their performance in the target population.
Little direct involvement of regulatory agencies in IVD
clinical trials was reported but all countries reported some
capacity for laboratory assessment of IVD. In addition
Burundi, Kenya, Tanzania (mainland) and Uganda reported
capacity for clinical trials for devices applicable to TB,
HIV and malaria. Formalized Technology Assessment
Programmes are absent in all EAC Partner States but both
Uganda and Kenya have research institutions with some
experience in technology assessment for IVD.
The quality of laboratory studies is critical for both
pre market evaluation and post market surveillance
and accreditation of laboratories is a highly desirable
prerequisite. Respondents from Kenya and Uganda reported
a number of laboratories accredited to international
standards and Tanzania is currently engaged in a programme
designed to lead to laboratory accreditation.
Table 3 Control of diagnostic and medical devices in EAC Partner States
Country Burundi Kenya Rwanda Tanzania
Mainland
Tanzania
Zanzibar
Uganda
Are medical devices regulated
by a National Authority
Some Some Programme
only (MOH)
Yes Joint with Mainland
(TFDA)
Yes
Regulation of in-vitro diagnostics Not yet In development Programme
only (MOH)
Yes Joint with TFDA Guidelines (Allied Health
Professionals Council of Uganda)
Regulation of IVDs in the
private sector
Not yet In development N/A Yes Joint with TFDA Guidelines (Allied Health
Professionals Council of Uganda)
Regulation lab reagents and
stains for diagnostics use
Import
controls
In development N/A Yes Joint with TFDA Guidelines (Allied Health
Professionals Council of Uganda)
Regulation of diagnostic tests
for veterinary use
None In development None Yes Joint with TFDA Yes
Pre-market control on IVDs None None Programme only1 Yes Joint with TFDA None
Post market control on IVDs None None Programme only1 Yes Joint with TFDA None
1Control programmes supported by donor aid e.g. TB, HIV/AIDS, Malaria.
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Priorities
When asked to state priorities for harmonization the most
common response across respondents was the need to
harmonize regulation of rapid diagnostic tests for important
diseases, with malaria, TB and HIV given as examples. The
need to strengthen existing National Regulatory Authorities
was also highlighted. Suggestions for future harmonization
activities included use of a common nomenclature
and definitions, mutual recognition and reducing the
number of clinical trials. Priorities for capacity building
most frequently included training to improve and maintain
the knowledge base and skills of personnel. Areas where
support was requested included dossier evaluation and
review, development of protocols and Standard Operating
Procedures, quality management systems and post market
monitoring and surveillance. Some respondents recognised
the need to differentiate training dependant on role, recog-
nising expertise in clinical trials or review of submission
dossiers.
Recommendations
Following review of the data and the expert meeting of
stakeholders from EAC Partner States, a series of general
recommendations were made as listed below. The
recommendations were made in the context of opportun-
ities for harmonizing regulation to accelerate access to
affordable and safe new products. Topics covered included
the legal framework, product nomenclature and classifica-
tion and mechanisms of harmonizing regulation including
formation of technical working groups and task forces,
communication platform within the region and use of
global guidelines and relationship to other working
harmonization parties.
List of recommendations arising from stakeholders
meeting
a. Diagnostic products should be considered a priority for
regulatory harmonisation in EAC Partner States and
there should be an extension plan for the regulatory
framework to cover medical devices in the longer term.
b. Each Partner State should have a legal and policy
framework for medical diagnostics and devices
suitable for harmonisation. The EAC should
collaborate with EAC partner states to expedite
IVDs and medical devices legislation and policy
framework where it does not exist; and to identify
refinement areas to existing ones where it is already
in the law system.
c. Common nomenclature and product classifications
should be used across the EAC
d. Partner States should develop mechanisms and
capacity for regulation that would feed into EAC
harmonised regulation
e. EAC and Partner States should establish a
communication platform to enable the necessary
exchange of information relating to medical
diagnostics and medical devices in order to provide
prompt safety information for the nations to
safeguard patients.
f. There is need for donor support with regard to
medical diagnostics for:
 Facilitating appropriate legal frame work in each
partner states as a matter of urgency
 Capacity building and training needs support for
NRA;
 Facilitating harmonisation in the EAC partner
states
 Facilitating formation of a Pan African
Harmonisation Working Party (PAHWP)
g. Technical Working Groups should be established to
pursue harmonization activities.
h. An EAC Regional Task Force on Harmonization and
Regulation of Medical Diagnostics and Medical
Devices should be established
i. The task force should lead to the establishment of a
Pan-African Harmonization Working Party
(PAHWP)
j. Harmonization activities should be undertaken with
consideration to guidelines issued by the Global
Harmonization Task Force and activities of other
regional bodies such as the Asian Harmonization
Working Party.
Conclusions
This study was undertaken to inform the EAC Secretariat
and EAC Partner States of the current status of regulatory
activities for medical devices and medical diagnostics
within the EAC region. Data and opinions collected
indicate that regulation of medical devices and
in vitro diagnostics is a neglected area. Regulation is
weak across the region, and although the majority of
Member States have a legal mandate to regulate medical
devices there is limited capacity to do so. Responses
received suggest that harmonization and streamlining
regulation in the EAC is seen as a positive aspiration. That
rapid IVD to detect important infectious diseases are seen
as a priority for harmonisation is not surprising in light of
health needs in this region of Africa. However, a limitation
of the study is that due to restraints of time and finance
the list of stakeholders consulted was not exhaustive and
it is possible that those who were not available for
comment would be less enthusiastic about the regulation
of IVD and medical devices. Several respondents indicated
that policy reviews are being undertaken and at least one
State (Tanzania) is proposing changes to the current regu-
latory framework and process. The collaboration between
the NRAs in United Republic of Tanzania is fertile ground
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for regulatory harmonisation process in the region. Future
activities planned include establishing a Task Force and
Technical Working Groups to take forward strengthening
and streamlining regulatory activities in the EAC and it is
clear that investment shall be needed to increase capacity.
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